Noninvasive biomarkers should be applied to clinical practice to reduce unnecessary biopsies.12 In future, CK18 can be used for monitoring the disease status as well as evaluating the response to the treatment in NAFLD. Here, KRT18 is linked to metabolic dysfunction-associated steatotic liver disease.